Fingerprint
Dive into the research topics where Christine Højte Dahl is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Research output
- 9 Journal article
-
Bone health after 3 years of ETI therapy: a real-world study from the Danish cystic fibrosis cohort
Henriksen, E. H., Nielsen, B. U., Jensen, C. B., Bryrup, T., Dahl, C. H., Bader-Larsen, K., Leo-Hansen, C., Olsen, M. F., Jeppesen, M., Oturai, P., Schwarz, P., Langdahl, B., Almdal, T., Faurholt-Jepsen, D., Mathiesen, I. H. M. & TransformCF study group, 18 Feb 2026, (E-pub ahead of print) In: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.Research output: Contribution to journal › Journal article › Research › peer-review
-
Real-World Improvements of Lung Clearance Index and Ventilation Distribution Efficiency in Children With Cystic Fibrosis After Elexacaftor/Tezacaftor/Ivacaftor Initiation
Henriksen, E. H., Sandvik, R. M., Olsen, M. F., Pressler, T., Bryrup, T., Leo-Hansen, C., Nielsen, B. U., Højte, C., Skov, M., Buchvald, F., Mathiesen, I. H. M., Qvist, T., Olesen, H. V., Rubak, S., Jensen, C. B., Faurholt-Jepsen, D., Nielsen, K. G. & TransformCF study group, Jun 2025, In: Pediatric Pulmonology. 60, 6, e71166.Research output: Contribution to journal › Journal article › Research › peer-review
3 Citations (Scopus) -
Severe hepatotoxicity is uncommon following the introduction of Elexacaftor/Tezacaftor/Ivacaftor: A real-world two-years follow-up study of the Danish cystic fibrosis cohort
Højte, C., Olsen, M. F., Faurholt-Jepsen, D., Jørgensen, M. H., Pressler, T., Leo-Hansen, C., Bryrup, T., Jeppesen, M., Olesen, H. V., Petersen, J., Katzenstein, T. L., Nielsen, B. U., Skov, M. & TransformCF study group, Sept 2025, In: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society. 24, 5, p. 998-1005 8 p.Research output: Contribution to journal › Journal article › Research › peer-review
3 Citations (Scopus) -
Lung function improvement on triple modulators: high-resolution, nationwide data from the Danish Cystic Fibrosis Cohort
Leo-Hansen, C., Faurholt-Jepsen, D., Qvist, T., Højte, C., Nielsen, B. U., Bryrup, T., Henriksen, E. H., Katzenstein, T., Skov, M., Mathiesen, I. H. M., Jeppesen, M., Jensen-Fangel, S., Olesen, H. V., Buchvald, F. F., Nielsen, K. G., Jimenez-Solem, E., Ritz, C., Pressler, T., Olsen, M. F. & TransformCF study group, Nov 2024, In: ERJ Open Research. 10, 6, 12 p., 00339-2024.Research output: Contribution to journal › Journal article › Research › peer-review
8 Citations (Scopus) -
Novel germline TP53 variant (p.(Phe109Ile)) confer high risk of cancer
Byrjalsen, A., Stoltze, U. K., Lautrup, C., Christensen, L. L., Mikkelsen, T., Hjalgrim, L., Brok, J. S., Dahl, C., Schmiegelow, K., Borgwardt, L., Diness, B. R., Hansen, T. V. O. & Wadt, K. A. W., 23 Oct 2024, In: Journal of Medical Genetics. 61, 11, p. 1023-1025 3 p., jmg-2024-110255.Research output: Contribution to journal › Journal article › Research › peer-review